Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150399 | 0.95 | RXRA (0.34) | TACR1GRM5KIF11GPBAR1RXRA | |
| SCHEMBL20156275 | 0.93 | PTGER4 (0.34) | PTGER4PDPK1TACR1GRM5KIF11 | |
| SCHEMBL20849586 | 0.90 | PTGER4 (0.39) | PTGER4PDPK1TACR1GRM5KIF11 | |
| SCHEMBL21090888 | 0.90 | GRIN1 (0.35) | PDPK1TACR1RXRARXRGGRIN1 | |
| SCHEMBL20156216 | 0.90 | RXRA (0.34) | PTGER4TACR1GRM5KIF11RXRA | |
| SCHEMBL20150382 | 0.90 | KIF11 (0.42) | PTGER4PDPK1GRM5KIF11GPBAR1 | |
| SCHEMBL21109745 | 0.89 | KIF11 (0.33) | KIF11GPBAR1GRIN1GRIN2BMEN1 | |
| SCHEMBL20654896 | 0.89 | KIF11 (0.35) | TACR1KIF11RXRAMEN1KMT2A | |
| SCHEMBL20114584 | 0.89 | PTGER4 (0.36) | PTGER4PDE10AELANEMEN1KMT2A | |
| SCHEMBL20150357 | 0.89 | PTGER4 (0.33) | PTGER4PDPK1GRM5KIF11GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | CYNORA GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, EPCAM, F12 | PTGER4 1809/4885PDPK1 4159/4885TACR1 1393/4885 |
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | OR10J3, EPCAM, F12 | PTGER4 1809/4885PDPK1 4159/4885TACR1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.